Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BOOTS/HOECHST CELANESE TO COLLABORATE ON BULK IBUPROFEN production in the U.S. via a 50/50 joint venture, the companies announced in an April 21 press release. "The partners expect to install in the United States a commercial facility which will use Hoechst Celanese technology. The facility is expected to come on stream in 1991," the two companies said. An ibuprofen production line will be built in one of Hoechst Celanese's three existing manufacturing plants in Texas. The installation of the ibuprofen manufacturing line is expected to require capital costs of $ 35 mil., the companies noted. The new plant will have the capacity to produce 2,500 metric tons of bulk ibuprofen annually, Boots predicted. Boots, which discovered ibuprofen, currently supplies the worldwide market for bulk ibuprofen from a 3,000-ton-per-year facility in Nottingham, England, the company said. The Nottingham plant provides bulk ibuprofen to Boots Pharmaceuticals in Shreveport, Louisiana for the production of Rufen and to American Home Products for the manufacture of Advil. Boots used to supply Upjohn with bulk ibuprofen. Boots' primary competitor in the U.S. bulk ibuprofen market is Ethyl Corp., which is currently the only U.S. manufacturer of bulk ibuprofen. Ethyl also exports its bulk ibuprofen. Ethyl noted that it will soon have the capacity to produce over 2,300 metric tons of ibuprofen annually.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts